Latest News on CSTL

Financial News Based On Company


Advertisement
Advertisement

Form 4 Castle Biosciences Inc: Derek J. Maetzold (Director, Pres. & Chief Exec. Officer) For: 16 November

https://uk.investing.com/news/stock-market-news/form-4-castle-biosciences-inc-derek-j-maetzold-director-pres--chief-exec-officer-for-16-november-93CH-4993422
This article reports on a Form 4 filing for Castle Biosciences Inc., indicating an insider transaction involving Derek J. Maetzold, who serves as Director, President, and Chief Executive Officer. The filing pertains to activity on November 16, but no details of the transaction itself are provided. The content is primarily a placeholder for the actual SEC filing.

Derek Maetzold, Castle Biosciences CEO, sells $228,530 in shares By Investing.com

https://uk.investing.com/news/stock-market-news/derek-maetzold-castle-biosciences-ceo-sells-228530-in-shares-93CH-4993409
Derek J. Maetzold, President and CEO of Castle Biosciences Inc., sold 6,942 shares of company stock for $228,530 on November 16, 2026. These transactions, executed under a Rule 10b5-1 trading plan, involved both direct and indirect sales through trusts. The sales occurred as Castle Biosciences stock trades near $33.38, with InvestingPro analysis suggesting it is slightly overvalued despite a 74% surge in the past six months and analyst price targets between $40 and $60.

CSTL: 24% revenue growth and higher guidance; TissueCypher and pipeline underpin expansion plans

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4687950:0-cstl-24-revenue-growth-and-higher-guidance-tissuecypher-and-pipeline-underpin-expansion-plans/
Castle Biosciences (CSTL) reported a 24% year-over-year revenue growth in Q3 and raised its full-year guidance to $385M-$395M. The company's growth strategy focuses on increasing TissueCypher adoption, expanding AdvanceAD-Tx, and investing in its pipeline, with melanoma volumes projected to grow at a mid-single-digit rate. This information is based on the company's 2026 Stephens Annual Investment Conference audio transcript.

Research Analysts Set Expectations for CSTL FY2026 Earnings

https://www.marketbeat.com/instant-alerts/estimates-research-analysts-set-expectations-for-cstl-fy2026-earnings-2026-11-16/
KeyCorp has forecasted a FY2026 earnings loss of $0.82 per share for Castle Biosciences (NASDAQ:CSTL), maintaining an "Overweight" rating and a $40 price target, with a projected narrower loss of $0.11 per share in FY2027. The company recently surpassed analyst expectations for its quarterly loss and revenue. Overall, analysts have a "Moderate Buy" consensus rating for CSTL, with a target price of $46.50.

Form 4 Castle Biosciences Inc: Derek J. Maetzold (Director, Pres. & Chief Exec. Officer) For: 11 September

https://in.investing.com/news/stock-market-news/form-4-castle-biosciences-inc-derek-j-maetzold-director-pres--chief-exec-officer-for-11-september-93CH-5705570
This article reports on a Form 4 filing for Castle Biosciences Inc., indicating an insider transaction by Derek J. Maetzold, who holds the positions of Director, President, and Chief Executive Officer. The filing pertains to activity on September 11. The article provides no further details on the nature of the transaction beyond the individual and date.
Advertisement

Castle Biosciences CEO Maetzold sells $464,870 in shares

https://www.investing.com/news/insider-trading-news/castle-biosciences-ceo-maetzold-sells-464870-in-shares-93CH-5028264
Derek J. Maetzold, President and CEO of Castle Biosciences Inc. (NASDAQ:CSTL), sold common stock worth $464,870 on September 11, 2026, under a Rule 10b5-1 trading plan. This sale followed a 76.63% stock return over six months, with shares trading at $33.79. Concurrently, Maetzold acquired 8,584 shares through stock options exercise for $20,515.

Form 4 Castle Biosciences Inc: Derek J. Maetzold (Director, Pres. & Chief Exec. Officer) For: 11 September

https://ca.investing.com/news/stock-market-news/form-4-castle-biosciences-inc-derek-j-maetzold-director-pres--chief-exec-officer-for-11-september-93CH-4959478
This article reports on a Form 4 filing for Castle Biosciences Inc., detailing a transaction made by Derek J. Maetzold, who serves as a Director, President, and Chief Executive Officer of the company. The filing pertains to activity on September 11. No further details about the transaction are provided in the snippet.

Castle Biosciences CCO Tobin W. sells $222,620 in shares By Investing.com

https://ca.investing.com/news/stock-market-news/castle-biosciences-cco-tobin-w-sells-222620-in-shares-93CH-4959102
Tobin W. Juvenal, Chief Commercial Officer at Castle Biosciences Inc. (NASDAQ:CSTL), sold 6,600 shares of company stock for a total of $222,620 in mid-September. These transactions were executed under a Rule 10b5-1 trading plan. The sales occurred after the stock had seen a 77% surge over the past six months, though it is currently trading near its Fair Value according to InvestingPro analysis.

Form 4 Castle Biosciences Inc: Tobin W. Juvenal (Chief Commercial Officer) For: 14 September

https://uk.investing.com/news/stock-market-news/form-4-castle-biosciences-inc-tobin-w-juvenal-chief-commercial-officer-for-14-september-93CH-4983124
This article reports on a Form 4 filing for Castle Biosciences Inc., indicating a transaction involving Tobin W. Juvenal, the Chief Commercial Officer. The filing pertains to activity on September 14th. The article is a brief financial market news update.

Castle Biosciences CCO Tobin W. sells $222,620 in shares By Investing.com

https://uk.investing.com/news/stock-market-news/castle-biosciences-cco-tobin-w-sells-222620-in-shares-93CH-4983122
Tobin W. Juvenal, Chief Commercial Officer at Castle Biosciences Inc., sold a total of 6,600 shares worth $222,620 in two transactions in mid-September under a Rule 10b5-1 trading plan. The sales occurred after the stock surged 77% over six months, with the company also reporting strong Q3 results, surpassing revenue and adjusted EPS expectations, and raising its full-year revenue outlook.
Advertisement

Form 4 Castle Biosciences Inc: Tobin W. Juvenal (Chief Commercial Officer) For: 14 September

https://ng.investing.com/news/stock-market-news/form-4-castle-biosciences-inc-tobin-w-juvenal-chief-commercial-officer-for-14-september-93CH-2808418
This article reports on a Form 4 filing for Castle Biosciences Inc., detailing insider transaction information for Tobin W. Juvenal, the Chief Commercial Officer. The filing is related to activity on September 14. The article primarily serves as a notice of this regulatory disclosure.

Castle Biosciences (CSTL) officer exercises $29.50 options and sells shares at a $35.07 average.

https://www.stocktitan.net/sec-filings/CSTL/form-4-castle-biosciences-inc-insider-trading-activity-fc4790d6dbbb.html
Tobin W. Juvenal, Chief Commercial Officer at Castle Biosciences (CSTL), exercised options for 3,195 common shares at $29.50 per share and subsequently sold all 3,195 shares at a weighted-average price of $35.07 per share on November 11, 2026. This transaction resulted in an approximate pre-tax spread of $18,000, and Juvenal's direct common stock holdings remained at 32,737 shares after the transaction.

How Raised 2026 Guidance At Castle Biosciences Stock Has Changed Its Investment Story

https://simplywall.st/stocks/us/healthcare/nasdaq-cstl/castle-biosciences/news/how-raised-2026-guidance-at-castle-biosciences-stock-has-cha
Castle Biosciences (NasdaqGM:CSTL) recently increased its 2026 revenue guidance to US$385-US$395 million, driven by anticipated higher TissueCypher test volume and improved average selling prices. This update shifts the investment focus to execution and test adoption rather than immediate margin expansion, despite the company accepting deeper near-term operating losses. Investors will closely watch how payer coverage for assays like DecisionDx SCC and AdvanceAD Tx progresses, as this remains a key catalyst for sustained growth and profitability.

Castle Biosciences (NASDAQ:CSTL) Stock: Insider Tobin Juvenal Sells 2,828 Shares

https://www.marketbeat.com/instant-alerts/insider-castle-biosciences-nasdaq-cstl-stock-insider-tobin-juvenal-sells-2828-shares-2026-11-12/
Castle Biosciences (NASDAQ:CSTL) insider Tobin Juvenal sold 2,828 shares of the company's stock for approximately $99,093 on November 11th, reducing his total holdings by 7.95%. The sale was part of a pre-arranged Rule 10b5-1 trading plan. This transaction occurred after Castle Biosciences reported strong quarterly earnings, beating analyst expectations for both EPS and revenue, and with analysts maintaining a "Moderate Buy" consensus rating for the stock.

Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,288 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-castle-biosciences-nasdaq-cstl-insider-tobin-juvenal-sells-3288-shares-of-stock-2026-11-12/
Tobin Juvenal, an insider at Castle Biosciences (NASDAQ:CSTL), sold 3,288 shares of the company's stock for approximately $107,419 under a Rule 10b5-1 trading plan, reducing his holdings by 8.46%. The company recently reported better-than-expected earnings, with an EPS of -$0.13 and revenue of $101.95 million. Analysts currently rate Castle Biosciences as a "Moderate Buy" with an average price target of $46.50.
Advertisement

Form 144 CASTLE BIOSCIENCES For: 12 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-castle-biosciences-for-12-november-93CH-4977681
This article from Investing.com announces the filing of Form 144 for Castle Biosciences (CSTL) on November 12, 2026. Form 144 typically relates to the intent to sell restricted or control securities. The brief notice provides the stock symbol for Castle Biosciences and indicates the date of the filing.

A $112K sale notice at Castle Biosciences (CSTL) covers 3,195 shares from an officer’s option exercise.

https://www.stocktitan.net/sec-filings/CSTL/144-castle-biosciences-inc-sec-filing-76110972b698.html
Tobin Juvenal, an officer at Castle Biosciences (CSTL), has filed a notice to sell 3,195 common shares with an aggregate market value of $112,032.68. These shares were acquired through a cash-paid stock option exercise on November 11, 2026. The filing notes that the report was made on November 12, 2026, due to a federal holiday preventing EDGAR filings on the previous day.

A live audio webcast will carry Castle Biosciences' Dec. 2 conference talk.

https://www.stocktitan.net/news/CSTL/castle-biosciences-to-present-at-the-piper-sandler-38th-annual-gbbob8qhnewp.html
Castle Biosciences (Nasdaq: CSTL) announced that its executive management is scheduled to present a company overview at the Piper Sandler 38th Annual Healthcare Conference on Wednesday, Dec. 2, 2026, at 8:10 a.m. Eastern time. A live audio webcast of the presentation will be available on the company's investor relations website, with a replay accessible after the broadcast concludes. The company is a diagnostics firm focused on improving health through innovative tests, primarily in dermatologic and gastroenterological diseases.

Castle Biosciences to Present at the Piper Sandler 38th Annual Healthcare Conference

https://www.prnewswire.com/news-releases/castle-biosciences-to-present-at-the-piper-sandler-38th-annual-healthcare-conference-302935495.html
Castle Biosciences, Inc. announced its executive management is scheduled to present a company overview at the Piper Sandler 38th Annual Healthcare Conference on December 2, 2026, at 8:10 a.m. Eastern time. A live audio webcast of the presentation will be available on the company's investor relations website, with a replay accessible afterwards. Castle Biosciences is a diagnostics company focused on dermatologic and gastroenterological diseases, providing innovative tests to guide patient care.

DecisionDx®-Melanoma Data at SDPA and Dermato-Onco2026 Support the...

https://www.quantisnow.com/insight/decisiondx-melanoma-data-at-sdpa-and-dermato-onco2026-support-the-tests-ability-6785144
Castle Biosciences (CSTL) is presenting new DecisionDx-Melanoma data at two dermatology conferences in November 2026. The data supports the test's ability to identify higher-risk patients within a group traditionally considered low risk, potentially aiding physician adoption. This release focuses on clinical value rather than new financial results.
Advertisement

BTIG Research Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock

https://www.marketbeat.com/instant-alerts/analyst-btig-research-forecasts-strong-price-appreciation-for-castle-biosciences-nasdaq-cstl-stock-2026-11-10/
BTIG Research has raised its price target for Castle Biosciences (NASDAQ:CSTL) to $52 from $44, reiterating a "buy" rating and implying a potential upside of 51.25%. The company recently reported better-than-expected quarterly earnings and revenue. Despite some insider selling, institutional investors have been increasing their stakes in the molecular diagnostics company, which focuses on cancer diagnosis and treatment guidance.

Form 144 Castle Biosciences For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-castle-biosciences-for-9-november-93CH-4944817
This article reports on the filing of Form 144 for Castle Biosciences on November 9, 2026. The brief announcement, published by Investing.com, indicates a filing related to the company's securities, often associated with an insider's intent to sell restricted or controlled stock. The article includes the stock symbol CSTL, which saw a 5.72% increase.

Baird maintains Castle Biosciences at Outperform, raises price target to $41 from $39

https://www.tradingview.com/news/tradingview:1adafab9cac2f:0-baird-maintains-castle-biosciences-at-outperform-raises-price-target-to-41-from-39/
Baird has reiterated its Outperform rating for Castle Biosciences (CSTL) and increased its price target from $39 to $41, marking a 5.1% rise. This new price target suggests a potential upside of 26.1% compared to the stock's closing price of $32.52 on November 6. Investors can find more detailed price target data and analyst recommendations on TradingView's Forecasts tab and News Flow section.

Castle Biosciences Inc (CSTL) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...

https://sg.finance.yahoo.com/news/castle-biosciences-inc-cstl-q3-111705123.html
Castle Biosciences Inc (NASDAQ:CSTL) reported strong Q3 2026 results with revenue increasing 24% year-over-year to $102.9 million, primarily driven by a 47% growth in TissueCypher test report volume. The company raised its full-year 2026 revenue guidance and expects positive adjusted EBITDA for Q4 2026 and full year 2027. However, DecisionDx Melanoma growth slowed to mid-single digits, and DecisionDx SCC volume remains pressured due to the loss of Medicare coverage.

Castle Biosciences Inc (CSTL) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...

https://au.finance.yahoo.com/news/castle-biosciences-inc-cstl-q3-111705123.html
Castle Biosciences Inc. reported a significant 24% year-over-year revenue increase in Q3 2026, reaching $102.9 million, primarily driven by strong TissueCypher test volume growth. The company raised its full-year 2026 revenue guidance and anticipates continued positive adjusted EBITDA. Despite these gains, DecisionDx Melanoma growth slowed, and the company faced increased operating expenses, resulting in a net loss of $4.1 million.
Advertisement

What Castle Biosciences (CSTL) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:2e8418b6f094b:0-what-castle-biosciences-cstl-said-on-its-q3-earnings-call/
Castle Biosciences (CSTL) reported strong Q3 revenue growth of 24%, reaching $102.9 million, primarily due to high demand for its TissueCypher test, and subsequently raised its full-year 2026 revenue outlook to $385 million to $395 million. Despite a wider net loss, the company saw increased adjusted EBITDA and expects continued positive adjusted EBITDA. Management highlighted significant volume growth in TissueCypher tests and steady performance for DecisionDx-Melanoma, while addressing ongoing efforts for coverage and pricing for other products like AdvanceAD-Tx and DecisionDx-SCC.

Castle Biosciences Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62958231/castle-biosciences-q3-2026-earnings-call-transcript
Castle Biosciences reported strong third-quarter 2026 financial results, with revenue growing 24% year-over-year to $102.9 million, primarily driven by a 47% increase in TissueCypher test report volume. The company raised its full-year 2026 revenue guidance to $385-$395 million, reflecting confidence in continued growth. Despite a net loss, Castle Biosciences achieved a positive adjusted EBITDA of $12.7 million and maintained a strong cash position.

CSTL: TissueCypher growth lifted revenue, but losses and reimbursement uncertainty persist

https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3924340:0-cstl-tissuecypher-growth-lifted-revenue-but-losses-and-reimbursement-uncertainty-persist/
Castle Biosciences (CSTL) reported a 23.9% year-over-year increase in Q3 revenue, primarily driven by growth in its TissueCypher product, with nine-month revenue up 12.8%. Despite a stable gross margin of 74.7%, the company continues to experience losses. Key risks for the business remain centered on Medicare coverage and reimbursement uncertainties.

Castle Biosciences Inc. (CSTL) Tops Q3 EPS by 22c; Offers Guidance

https://www.streetinsider.com/Earnings/Castle+Biosciences+Inc.+%28CSTL%29+Tops+Q3+EPS+by+22c%3B+Offers+Guidance/27300704.html
Castle Biosciences Inc. (CSTL) exceeded Q3 analyst estimates, reporting an EPS of ($0.13), which was $0.22 better than expected, and revenue of $102.89 million, surpassing the consensus. The company also provided strong FY2026 revenue guidance, projecting $385-395 million against a consensus of $374.1 million.

CSTL: TissueCypher-led growth lifted Q3 revenue and drove a higher 2026 outlook

https://www.tradingview.com/news/urn:summary_document_report:quartr.com:3924339:0-cstl-tissuecypher-led-growth-lifted-q3-revenue-and-drove-a-higher-2026-outlook/
Castle Biosciences (CSTL) reported a 24% year-over-year increase in Q3 revenue, primarily driven by a 47% growth in TissueCypher report volume. This strong performance led the company to raise its 2026 revenue guidance to $385–395 million. While Adjusted EBITDA improved in Q3, the nine-month Adjusted EBITDA saw a decline compared to the previous year.
Advertisement

Castle Biosciences Beats And Raises For A Third Time As TissueCypher Carries A Softening Dermatology Franchise

https://finviz.com/news/418034/castle-biosciences-beats-and-raises-for-a-third-time-as-tissuecypher-carries-a-softening-dermatology-franchise
Castle Biosciences (CSTL) reported a significant third-quarter beat on revenue and raised its full-year guidance for the third consecutive time, largely driven by strong performance from its TissueCypher product. While TissueCypher volumes and pricing are robust, other legacy dermatology products are softening, and critical reimbursement catalysts have slipped, creating a complex outlook despite improving operational profitability. The market reaction and future trends for TissueCypher, along with an upcoming CMS decision, will be crucial.

Castle Biosciences (CSTL) Stock Could Be Cheap Following Its 109% Run

https://simplywall.st/stocks/us/healthcare/nasdaq-cstl/castle-biosciences/news/castle-biosciences-cstl-stock-could-be-cheap-following-its-1
Castle Biosciences (CSTL) has seen its stock price increase by 108.7% over the past three years. This article explores whether the current valuation of US$35.75 per share is justified by its sales profile and market perception, noting its Price/Sales ratio of 3.1x compared to sector averages. Analyst narratives present both bull and bear cases, with some seeing the company as undervalued due to an expanding test menu, while others express concerns about rising operating expenses.

Form 144 Castle Biosciences For: 2 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-castle-biosciences-for-2-november-93CH-4923607
This article announces the filing of Form 144 by Castle Biosciences (CSTL) for November 2nd. Form 144 is a notice of the intent to sell restricted securities, which can indicate insider activity or large share dispositions. The article itself is brief, primarily serving as a notification rather than an in-depth analysis.

An officer and two trusts plan to sell 21,438 Castle Biosciences (CSTL) shares.

https://www.stocktitan.net/sec-filings/CSTL/144-castle-biosciences-inc-sec-filing-e0341d5852f0.html
Castle Biosciences (CSTL) officer Derek Maetzold and two related trusts propose selling a total of 21,438 common shares, valued at approximately $749,043.72. This planned sale, set for November 2, 2026, is part of a Rule 10b5-1(c) compliant selling plan established on June 2, 2026. The filing details individual share allocations for Derek Maetzold and the two trusts, along with a history of previous sales.

Castle Biosciences (CSTL) Dropped, So What Is Driving Attention Now?

https://simplywall.st/stocks/us/healthcare/nasdaq-cstl/castle-biosciences/news/castle-biosciences-cstl-dropped-so-what-is-driving-attention
Castle Biosciences (CSTL) has shown mixed returns recently, with a slight daily drop but strong weekly and monthly gains. The stock is considered 18% undervalued based on test volumes, reimbursement decisions, and cash reserves, despite its P/S ratio being higher than the industry average. Key risks include unresolved Medicare coverage for DecisionDx SCC and pressure on gross margins from newer tests.
Advertisement

Castle Biosciences (NASDAQ:CSTL) Stock Rating Raised to Buy at Wall Street Zen

https://www.marketbeat.com/instant-alerts/analyst-castle-biosciences-nasdaq-cstl-stock-rating-raised-to-buy-at-wall-street-zen-2026-11-01/
Wall Street Zen has upgraded Castle Biosciences (NASDAQ:CSTL) from a "hold" to a "buy" rating, contributing to a consensus "Moderate Buy" rating among analysts with an average price target of $44.25. The company recently exceeded analyst estimates with quarterly revenue of $99.86 million and adjusted earnings per share of $(0.07). Despite recent insider stock sales, institutional investors and hedge funds hold a significant 92.6% stake in the molecular diagnostics company.

How (CSTL) Movements Inform Risk Allocation Models

https://news.stocktradersdaily.com/news_release/21/How_CSTL_Movements_Inform_Risk_Allocation_Models_103126035202_1793476322.html
This article analyzes Castle Biosciences Inc. (NASDAQ: CSTL) using AI models to inform risk allocation. Key findings indicate strong near- and mid-term sentiment but a weak long-term outlook, with no resistance levels above the current price suggesting upside potential. The analysis provides specific position, momentum breakout, and risk hedging trading strategies tailored to different risk profiles.

Earnings Preview: CSTL to Report Financial Results Post-market on November 05

https://www.moomoo.com/news/post/1003075088/earnings-preview-cstl-to-report-financial-results-post-market-on
This article announces that Castle Biosciences, Inc. (CSTL) is scheduled to report its third-quarter financial results after the market closes on November 5, 2026. The company will also host a conference call and webcast to discuss these results.

Under a preset trading plan, Castle Biosciences (CSTL) executive sells 6,578 shares.

https://www.stocktitan.net/sec-filings/CSTL/form-4-castle-biosciences-inc-insider-trading-activity-4c9d80c2c37f.html
Castle Biosciences Inc.'s Chief Commercial Officer, Tobin W. Juvenal, sold a total of 6,578 shares on October 28, 2026, under a Rule 10b5-1 trading plan adopted in May 2026. The shares were sold in two separate transactions at weighted-average prices of $35.577 and $36.619 per share. These sales were executed in multiple trades within specified price ranges.

CSTL Q3'26 Earnings: revenue estimate is 92.41M USD

https://www.tradingview.com/news/tradingview:1fabf2af27005:0-cstl-q3-26-earnings-revenue-estimate-is-92-41m-usd/
Castle Biosciences, Inc. (CSTL) is scheduled to release its Q3'26 earnings on November 5, after market close, with an expected disclosure time of 4:05 PM ET. Analysts estimate revenue for Q3'26 to be $92.41 million USD and earnings per share (EPS) at ($0.35) USD. The article also provides a table comparing reported and estimated revenue and EPS for recent quarters, highlighting past surprises.
Advertisement

An investor reports 1.5 million Castle Biosciences (CSTL) shares with shared voting power.

https://www.stocktitan.net/sec-filings/CSTL/schedule-13g-a-castle-biosciences-inc-amended-passive-investment-disc-a7aa8ee4c767.html
Principal Global Investors reported beneficial ownership of 1,500,897 shares, representing 4.9% of Castle Biosciences Inc. (CSTL) common stock, as of September 30, 2026. The investment firm holds shared voting and dispositive power over these shares. This disclosure was made via an amended Schedule 13G/A filing.

Is Castle Biosciences (CSTL) Priced About Right After A 134% Rise?

https://simplywall.st/stocks/us/healthcare/nasdaq-cstl/castle-biosciences/news/is-castle-biosciences-cstl-priced-about-right-after-a-134-ri
Castle Biosciences (CSTL) has seen a 134% share price increase over the last three years, prompting questions about whether its current US$36.68 price is justified by its sales. The stock's P/S ratio of 3.1x is higher than the industry average, indicating investors are paying a premium for its diagnostic tests. The valuation model suggests the current multiple is reasonable, but analysts are divided on whether the company's revenue quality and growth prospects justify this premium.

Mizuho Begins Coverage on Castle Biosciences (NASDAQ:CSTL)

https://www.marketbeat.com/instant-alerts/analyst-mizuho-begins-coverage-on-castle-biosciences-nasdaq-cstl-2026-10-29/
Mizuho has initiated coverage on Castle Biosciences (NASDAQ:CSTL) with an "outperform" rating and a $60 price target, suggesting a significant upside. The company has a consensus "Moderate Buy" rating from analysts and recently surpassed quarterly earnings and revenue expectations. Despite positive analyst sentiment, insiders have sold a notable amount of stock in the last 90 days.

Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Thursday

https://www.marketbeat.com/instant-alerts/upcoming-castle-biosciences-cstl-expected-to-announce-quarterly-earnings-on-thursday-2026-10-29/
Castle Biosciences (CSTL) is scheduled to release its Q3 2026 earnings on Thursday, November 5th, with analysts predicting a loss of $0.3544 per share on revenue of $92.41 million. The company previously surpassed expectations in Q2 2026, reporting a smaller loss and higher revenue than anticipated. Despite a "Moderate Buy" consensus rating and a $42.00 average price target, company insiders have sold approximately $6.98 million worth of stock in the last 90 days.

Tobin Juvenal, Castle Biosciences CCO, sells $108,767 in stock By Investing.com

https://ng.investing.com/news/stock-market-news/tobin-juvenal-castle-biosciences-cco-sells-108767-in-stock-93CH-2764879
Tobin W. Juvenal, Chief Commercial Officer at Castle Biosciences Inc. (NASDAQ:CSTL), sold 3,288 shares of company stock for $108,767 on October 26, 2026. This sale was conducted under a Rule 10b5-1 trading plan. The article also notes that Castle Biosciences recently surpassed Wall Street expectations for profit and revenue, leading to a raised price target from BTIG.
Advertisement

Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 3,288 Shares of Company Stock

https://www.marketbeat.com/instant-alerts/insider-castle-biosciences-nasdaq-cstl-insider-tobin-juvenal-sells-3288-shares-of-company-stock-2026-10-28/
Castle Biosciences (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of the company's stock, valued at approximately $108,767, reducing his holdings by 6.75%. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider sale, CSTL shares rose 6.3% on Wednesday, and the company recently reported quarterly results that beat analyst expectations.

Form 4 Castle Biosciences Inc: Tobin W. Juvenal (Chief Commercial Officer) For: 26 October

https://uk.investing.com/news/stock-market-news/form-4-castle-biosciences-inc-tobin-w-juvenal-chief-commercial-officer-for-26-october-93CH-4939138
This article reports on a Form 4 filing for Castle Biosciences Inc., specifically concerning Tobin W. Juvenal, the Chief Commercial Officer. The filing is dated for October 26. The article itself is a brief announcement from Investing.com.

Under a trading plan, Castle Biosciences (CSTL) officer sells 3,288 shares at an average $33.08.

https://www.stocktitan.net/sec-filings/CSTL/form-4-castle-biosciences-inc-insider-trading-activity-60c2b966fe58.html
Tobin W. Juvenal, Chief Commercial Officer of Castle Biosciences Inc. (CSTL), sold 3,288 shares on October 26, 2026, at a weighted-average price of $33.08 per share. This transaction was carried out under a Rule 10b5-1 plan adopted in May 2026, leaving him with 45,431 shares directly after the sale. The sale generated approximately $109,000, with individual trade prices ranging from $32.63 to $33.46.

Castle Biosciences to Participate in Upcoming Investor Conferences

https://www.prnewswire.com/news-releases/castle-biosciences-to-participate-in-upcoming-investor-conferences-302921046.html
Castle Biosciences, Inc. (Nasdaq: CSTL) announced its executive management will present a company overview at the Stephens Annual Investment Conference on Wednesday, November 18, 2026, at 12:30 p.m. Central time. A live audio webcast will be available on the company's website. Additionally, Castle Biosciences will hold one-on-one investor meetings at the Jefferies Global Healthcare Conference from November 16-19, 2026.

Tobin Juvenal, Castle Biosciences CCO, sells $108,767 in stock

https://www.investing.com/news/insider-trading-news/tobin-juvenal-castle-biosciences-cco-sells-108767-in-stock-93CH-4980735
Tobin Juvenal, Chief Commercial Officer at Castle Biosciences Inc., sold 3,288 shares of the company's common stock for a total of $108,767 on October 26, 2026. This sale was executed under a Rule 10b5-1 trading plan adopted in May 2026, leaving him with 45,431 shares directly held. The article notes that the stock has since climbed and is considered potentially overvalued according to InvestingPro analysis, despite recent strong Q2 results and increased price targets from analysts like BTIG.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement